JP2018535647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535647A5 JP2018535647A5 JP2018513423A JP2018513423A JP2018535647A5 JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5 JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018513423 A JP2018513423 A JP 2018513423A JP 2018535647 A5 JP2018535647 A5 JP 2018535647A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- ile
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 108091008874 T cell receptors Proteins 0.000 claims 19
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 1
- 108010037618 HLA-C*08 antigen Proteins 0.000 claims 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 241000713810 Rat sarcoma virus Species 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022188263A JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218688P | 2015-09-15 | 2015-09-15 | |
| US62/218,688 | 2015-09-15 | ||
| PCT/US2016/050875 WO2017048593A1 (en) | 2015-09-15 | 2016-09-09 | T cell receptors recognizing hla-cw8 restricted mutated kras |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188263A Division JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535647A JP2018535647A (ja) | 2018-12-06 |
| JP2018535647A5 true JP2018535647A5 (enExample) | 2019-10-17 |
| JP7185524B2 JP7185524B2 (ja) | 2022-12-07 |
Family
ID=56985686
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513423A Active JP7185524B2 (ja) | 2015-09-15 | 2016-09-09 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
| JP2022188263A Active JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022188263A Active JP7461445B2 (ja) | 2015-09-15 | 2022-11-25 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10556940B2 (enExample) |
| EP (2) | EP3350213B1 (enExample) |
| JP (2) | JP7185524B2 (enExample) |
| KR (2) | KR20250117744A (enExample) |
| CN (2) | CN108350059B (enExample) |
| AU (3) | AU2016323017B2 (enExample) |
| DK (1) | DK3350213T3 (enExample) |
| ES (1) | ES2879287T3 (enExample) |
| IL (1) | IL257840B2 (enExample) |
| MX (1) | MX2018003062A (enExample) |
| SA (1) | SA518391109B1 (enExample) |
| SG (1) | SG10201913868XA (enExample) |
| WO (1) | WO2017048593A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| PL3494133T3 (pl) * | 2016-08-02 | 2022-11-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t anty-kras-g12d |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP4234576A3 (en) * | 2017-03-31 | 2023-09-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of isolating neoantigen-specific t cell receptor sequences |
| WO2018213467A1 (en) * | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| EA202090652A1 (ru) * | 2017-09-20 | 2020-08-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| MA51043A (fr) * | 2017-12-04 | 2020-10-14 | Us Health | Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée |
| EP3810182A4 (en) * | 2018-06-19 | 2022-08-24 | BioNTech US Inc. | Neoantigens and uses thereof |
| JP2021533777A (ja) * | 2018-08-16 | 2021-12-09 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞受容体構築物およびその使用 |
| CN120607607A (zh) * | 2019-01-22 | 2025-09-09 | 美国卫生和人力服务部 | 针对含有g12r突变的ras的hla第ii类限制性t细胞受体 |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| WO2020210202A1 (en) * | 2019-04-11 | 2020-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| BR112022015897A2 (pt) * | 2020-02-14 | 2022-10-18 | Us Health | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v |
| CN111574616B (zh) * | 2020-06-17 | 2021-02-02 | 深圳豪石生物科技有限公司 | 分离的t细胞受体和应用 |
| CA3185483A1 (en) * | 2020-07-16 | 2022-01-20 | Noam LEVIN | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
| WO2022072760A1 (en) * | 2020-10-02 | 2022-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920824B (zh) * | 2022-05-27 | 2023-12-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301017B2 (en) * | 2002-05-30 | 2007-11-27 | Kolesnick Richard N | Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis |
| EP1545204B1 (en) | 2002-09-06 | 2016-08-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| PL2327763T3 (pl) * | 2005-08-05 | 2018-08-31 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | Generowanie komórek T specyficznych względem antygenu |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| BR112013006718B1 (pt) * | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP3392270B1 (en) | 2011-09-15 | 2020-08-26 | The United States of America, as Represented by the Secretary Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| PT3223850T (pt) | 2014-11-26 | 2020-04-13 | Us Health | Receptores de células t anti-kras mutado |
-
2016
- 2016-09-09 CN CN201680058891.3A patent/CN108350059B/zh active Active
- 2016-09-09 ES ES16770408T patent/ES2879287T3/es active Active
- 2016-09-09 DK DK16770408.9T patent/DK3350213T3/da active
- 2016-09-09 KR KR1020257025325A patent/KR20250117744A/ko active Pending
- 2016-09-09 IL IL257840A patent/IL257840B2/en unknown
- 2016-09-09 WO PCT/US2016/050875 patent/WO2017048593A1/en not_active Ceased
- 2016-09-09 US US15/758,954 patent/US10556940B2/en active Active
- 2016-09-09 SG SG10201913868XA patent/SG10201913868XA/en unknown
- 2016-09-09 KR KR1020187010326A patent/KR102841067B1/ko active Active
- 2016-09-09 EP EP16770408.9A patent/EP3350213B1/en active Active
- 2016-09-09 CN CN202111083392.9A patent/CN115073583A/zh active Pending
- 2016-09-09 AU AU2016323017A patent/AU2016323017B2/en active Active
- 2016-09-09 MX MX2018003062A patent/MX2018003062A/es unknown
- 2016-09-09 JP JP2018513423A patent/JP7185524B2/ja active Active
- 2016-09-09 EP EP21162567.8A patent/EP3901169B1/en active Active
-
2018
- 2018-03-13 SA SA518391109A patent/SA518391109B1/ar unknown
-
2020
- 2020-01-10 US US16/739,310 patent/US11667692B2/en active Active
-
2021
- 2021-02-10 AU AU2021200833A patent/AU2021200833B2/en active Active
-
2022
- 2022-07-26 AU AU2022209229A patent/AU2022209229B2/en active Active
- 2022-11-25 JP JP2022188263A patent/JP7461445B2/ja active Active
-
2023
- 2023-05-01 US US18/310,141 patent/US20230406904A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535647A5 (enExample) | ||
| IL273254B1 (en) | HLA type II-restricted T cell receptors against RAS | |
| JP2017536825A5 (enExample) | ||
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2015535816A5 (enExample) | ||
| JP2015525208A5 (enExample) | ||
| ES2984937T3 (es) | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1 | |
| JP2021505136A5 (enExample) | ||
| JP2020534828A5 (enExample) | ||
| AU2019403245B2 (en) | Antibodies that neutralize hepatitis B virus and uses thereof | |
| EP4480967A1 (en) | Development and use of novel immunomodulator | |
| JP2020511936A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| FI3294333T4 (fi) | Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit | |
| RS55822B1 (sr) | Terapijski peptidi | |
| JP2016503295A5 (enExample) | ||
| JP2017524372A5 (enExample) | ||
| RU2018128215A (ru) | Антитела против mica | |
| KR20180016321A (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
| JP2019536426A (ja) | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド | |
| RU2016124670A (ru) | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения | |
| CN113527473A (zh) | 一种全人源单克隆抗体及其应用 | |
| JP7140403B2 (ja) | Ｌｉｇｈｔに結合する抗原結合分子 | |
| CN110194799A (zh) | 结合犬pd-1的抗犬pd-1抗体 | |
| JP2017536821A5 (enExample) |